argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-10-08 08:10 |
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Up…
|
English | 166.4 KB | ||
| 2021-09-07 13:01 |
argenx to Present at Upcoming Investor Conferences
|
English | 19.7 KB | ||
| 2021-08-25 17:09 |
argenx Announces Validation of European Marketing Authorization Application for…
|
English | 43.6 KB | ||
| 2021-08-04 08:32 |
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
|
English | 15.9 KB | ||
| 2021-07-29 14:14 | English | 1.1 MB | |||
| 2021-07-29 08:29 |
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Bus…
|
English | 1.2 MB | ||
| 2021-07-22 08:14 |
argenx to Report Half Year 2021 Financial Results and Second Quarter Business U…
|
English | 19.0 KB | ||
| 2021-07-14 08:53 |
argenx to Host Virtual R&D Day on July 20, 2021
|
English | 28.0 KB | ||
| 2021-06-17 08:32 |
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for…
|
English | 52.2 KB | ||
| 2021-06-07 08:30 |
argenx to regain global rights to cusatuzumab
|
English | 46.8 KB | ||
| 2021-06-01 14:42 |
argenx Appoints Karl Gubitz as Chief Financial Officer
|
English | 44.7 KB | ||
| 2021-06-01 08:17 |
argenx to Present at Upcoming Investor Conferences
|
English | 21.4 KB | ||
| 2021-05-14 08:07 |
argenx Reports First Quarter 2021 Financial Results and Provides Business Update
|
English | 123.5 KB | ||
| 2021-05-12 08:42 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 178.1 KB | ||
| 2021-05-07 08:18 |
argenx to Report First Quarter 2021 Financial Results and Business Update on Ma…
|
English | 20.6 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
